Article
Synaptotoxicity of Alzheimer beta amyloid can be explained by its membrane perforating property.
Laboratory of Neurophysiology, Department of Physiology, University of Concepción, Concepción, Chile.
PLoS ONE (impact factor:
4.09).
01/2010;
5(7):e11820.
DOI:10.1371/journal.pone.0011820
pp.e11820
Source: PubMed
-
Article: Alzheimer's disease is a synaptic failure.
[show abstract] [hide abstract]
ABSTRACT: In its earliest clinical phase, Alzheimer's disease characteristically produces a remarkably pure impairment of memory. Mounting evidence suggests that this syndrome begins with subtle alterations of hippocampal synaptic efficacy prior to frank neuronal degeneration, and that the synaptic dysfunction is caused by diffusible oligomeric assemblies of the amyloid beta protein.Science 11/2002; 298(5594):789-91. · 31.20 Impact Factor -
Article: Intranasal NAP administration reduces accumulation of amyloid peptide and tau hyperphosphorylation in a transgenic mouse model of Alzheimer's disease at early pathological stage.
[show abstract] [hide abstract]
ABSTRACT: Accumulation of beta-amyloid (Abeta) peptide and hyperphosphorylation of tau in the brain are pathological hallmarks of Alzheimer's disease (AD). Agents altering these pathological events might modify clinical disease progression. NAP (Asn-Ala-Pro-Val-Ser-Ile-Pro-Gln) is an octapeptide that has shown neuroprotective effects in various in vitro and in vivo neurodegenerative models. Previous studies showed that NAP protected against Abeta-induced neurotoxicity, inhibited Abeta aggregation, and, by binding to tubulin, prevented disruption of microtubules. In this study, we investigated the effect of NAP on Abeta and tau pathology using a transgenic mouse model that recapitulates both aspects of AD. We administered NAP intranasally (0.5 microg/mouse per day, daily from Monday through Friday) for 3 mo, starting from 9 mo of age, which is a prepathological stage in these mice. NAP treatment significantly lowered levels of Abeta 1-40 and 1-42 in brain. In addition, NAP significantly reduced levels of hyperphosphorylated tau. Of particular interest, hyperphosphorylation at the threonine 231 site was reduced; phosphorylation at this site influences microtubule binding. Our results indicate that NAP treatment of transgenic mice initiated at an early stage reduced both Abeta and tau pathology, suggesting that NAP might be a potential therapeutic agent for AD.Journal of Molecular Neuroscience 02/2007; 31(2):165-70. · 2.50 Impact Factor -
Article: Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide.
[show abstract] [hide abstract]
ABSTRACT: The distinct protein aggregates that are found in Alzheimer's, Parkinson's, Huntington's and prion diseases seem to cause these disorders. Small intermediates - soluble oligomers - in the aggregation process can confer synaptic dysfunction, whereas large, insoluble deposits might function as reservoirs of the bioactive oligomers. These emerging concepts are exemplified by Alzheimer's disease, in which amyloid beta-protein oligomers adversely affect synaptic structure and plasticity. Findings in other neurodegenerative diseases indicate that a broadly similar process of neuronal dysfunction is induced by diffusible oligomers of misfolded proteins.Nature Reviews Molecular Cell Biology 03/2007; 8(2):101-12. · 39.12 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed.
The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual
current impact factor.
Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence
agreement may be applicable.
Keywords
Abeta
Abeta excess disrupts membranes
Abeta induces perforation
Abeta perforates"
alterations
block Abeta neurotoxicity
disease-modifying therapies
induce Alzheimer's disease
intracellular calcium
membrane protein
membrane-perforating action
native brain neuronal membranes
neuronal membranes
toxins
working hypothesis